Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Ludwig, H; Scheithauer, W; Kührer, I; Kuzmits, R; Gisslinger, G; Linkesch, W; Zielinski, C; Fritz, E.
Interferon therapy in multiple myeloma
ONKOLOGIE. 1988; 11(4): 192-196.
Doi: 10.1159/000216520
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Natural leukocyte interferon and recombinant interferon alpha-2 have effected remission rates between 10 and 20% in the treatment of multiple myeloma. Response rates have been higher in untreated patients than in relapsing or primarily refractory cases. Patients with slowly proliferating tumors, early tumor stage or IgA-monoclonal protein seem to show increased sensibility to interferon as compared to patients without those characteristics. First trials using combined interferon chemotherapy regimens suggest that the toxicity associated with this treatment modality remains acceptable. At present, however, one cannot definitely decide whether and to which degree the combination therapy will improve the response rates.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Combined Modality Therapy - therapeutic use
- Drug Evaluation - therapeutic use
- Humans - therapeutic use
- Interferon Alfa-2a - therapeutic use
- Interferon Type I, Recombinant - therapeutic use
- Multiple Myeloma - drug therapy
- Prognosis - drug therapy